Vertex spends billions on CRISPR technology in search of diabetes cure

A new billion-dollar agreement with US gene editing firm Arbor Biotechnologies marks a continuation of biotech company Vertex's efforts to develop stem cell treatments, with a special focus on diabetes.

Photo: Brian Snyder/Reuters/Ritzau Scanpix

US-based biotech company Vertex, known for its specialization within cystic fibrosis, has also been working towards a breakthrough for treating type 1 diabetes over the past few years. That innovation is now a step closer.

Vertex has now entered into an agreement with Arbor Biotechnologies, giving it access to Arbor's CRISPR gene editing platform. Vertex is paying an undisclosed sum involving milestone payments of up to DKK 7.6bn (USD 1.2bn), plus a percentage of eventual sales for the priviledge.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs